Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Lenti, MV; Ribaldone, DG; Borrelli, de, Andreis, F; Vernero, M; Barberio, B; De, Ruvo, M; Savarino, EV; Kav, T; Blesl, A; Franzoi, M; Gröchenig, HP; Pugliese, D; Ianiro, G; Porcari, S; Cammarota, G; Gasbarrini, A; Spagnuolo, R; Ellul, P; Foteinogiannopoulou, K; Koutroubakis, I; Argyriou, K; Cappello, M; Jauregui-Amezaga, A; Demarzo, MG; Silvestris, N; Armuzzi, A; Sottotetti, F; Bertani, L; Festa, S; Eder, P; Pedrazzoli, P; Lasagna, A; Vanoli, A; Gambini, G; Santacroce, G; Rossi, CM; Delliponti, M; Klersy, C; Corazza, GR; Di, Sabatino, A, , European, Consortium, for, the, study, of, immune, checkpoint, inhibitor-induced, colitis, , European, Consortium, for, the, study, of, immune, checkpoint, inhibitor-induced, colitis.
A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium.
ESMO Open. 2024; 9(7):103632 Doi: 10.1016/j.esmoop.2024.103632 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Co-authors Med Uni Graz

Blesl Andreas

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

BACKGROUND: Data regarding the clinical outcome of patients with immune checkpoint inhibitor (ICI)-induced colitis are scant. We aimed to describe the 12-month clinical outcome of patients with ICI-induced colitis. MATERIALS AND METHODS: This was a retrospective, European, multicentre study. Endoscopy/histology-proven ICI-induced colitis patients were enrolled. The 12-month clinical remission rate, defined as a Common Terminology Criteria for Adverse Events diarrhoea grade of 0-1, and the correlates of 12-month remission were assessed. RESULTS: Ninety-six patients [male:female ratio 1.5:1; median age 65 years, interquartile range (IQR) 55.5-71.5 years] were included. Lung cancer (41, 42.7%) and melanoma (30, 31.2%) were the most common cancers. ICI-related gastrointestinal symptoms occurred at a median time of 4 months (IQR 2-7 months). An inflammatory bowel disease (IBD)-like pattern was present in 74 patients (77.1%) [35 (47.3%) ulcerative colitis (UC)-like, 11 (14.9%) Crohn's disease (CD)-like, 28 (37.8%) IBD-like unclassified], while microscopic colitis was present in 19 patients (19.8%). As a first line, systemic steroids were the most prescribed drugs (65, 67.7%). The 12-month clinical remission rate was 47.7 per 100 person-years [95% confidence interval (CI) 33.5-67.8). ICI was discontinued due to colitis in 66 patients (79.5%). A CD-like pattern was associated with remission failure (hazard ratio 3.84, 95% CI 1.16-12.69). Having histopathological signs of microscopic colitis (P = 0.049) and microscopic versus UC-/CD-like colitis (P = 0.014) were associated with a better outcome. Discontinuing the ICI was not related to the 12-month remission (P = 0.483). Four patients (3.1%) died from ICI-induced colitis. CONCLUSIONS: Patients with IBD-like colitis may need an early and more aggressive treatment. Future studies should focus on how to improve long-term clinical outcomes.

Find related publications in this database (using NLM MeSH Indexing)

Humans - administration & dosage

Male - administration & dosage

Immune Checkpoint Inhibitors - adverse effects, therapeutic use

Female - administration & dosage

Middle Aged - administration & dosage

Retrospective Studies - administration & dosage

Aged - administration & dosage

Colitis - chemically induced

Follow-Up Studies - administration & dosage

Europe - administration & dosage

Find related publications in this database (Keywords)

colitis

immunotherapy

in fl iximab

nivolumab

pembrolizumab

© Med Uni Graz • Imprint